Erbitux is licensed (1) for treatment of patients with Epidermal Growth Factor Receptor (EGFR) expressing KRAS wild-type metastatic colorectal cancer (mCRC).

1. Erbitux SmPC June 2011

Please indicate on the invoicing section of the request form if your case is for funded KRAS testing.

UCL-AD offers free of charge KRAS testing service for ALL NHS colorectal cancer patients

UCL-AD can now offer a Merck Serono funded service for KRAS testing of tumour tissue samples from ALL NHS PATIENTS diagnosed with colorectal cancer (CRC).  Identifying patients with wild-type KRAS mCRC, who may benefit from a treatment regimen including Erbitux (Cetuximab). Mutation Analysis at UCL-AD is performed using the validated Qiagen Therascreen PCR Assays + inhouse fragment analysis where applicable.

For for information about KRAS testing at UCL-AD please contact:

Michael Gandy, Clinical Services Manager                      020 7679 6912 michael.gandy@uclad.com

Request forms are available for download from:  http://www.uclad.com/forms/MA_Request_Form.pdf

Also see UCL-AD EGFR NSCLC Testing Service update: Two years of testing experience, <2% failure rate, assay sensitive to 1% tumour, 5 day TAT

Click here to download the poster.